Table 1 Clinical baseline of 447 SKCM patients
From: Gene expression and immune infiltration in melanoma patients with different mutation burden
Variables | Number (%) |
|---|---|
Vital Status | |
 Alive | 239 (53.5%) |
 Dead | 208B (46.5%) |
 Age | 57.8 ± 15.6 |
Sex | |
 Male | 279 (62.4%) |
 Female | 168 (37.6%) |
Pathological Stage | |
 I/II NOS | 10 (2.3%) |
 Stage 0 | 6 (1.3%) |
 Stage I | 77 (17.2%) |
 Stage II | 131 (29.3%) |
 Stage III | 170 (38.0%) |
 Stage IV | 20 (4.5%) |
 Unknown | 33 (7.4%) |
AJCC-T Stage | |
 T0/Tis | 30 (6.7%) |
 T1 | 42 (9.4%) |
 T2 | 76 (17.0%) |
 T3 | 88 (19.7%) |
 T4 | 144 (32.2%) |
 TX | 42 (9.4%) |
 Unknown | 25 (5.6%) |
AJCC-N Stage | |
 N0 | 222 (49.7%) |
 N1 | 73 (16.3%) |
 N2 | 49 (11.0%) |
 N3 | 55 (12.3%) |
 NX | 31 (6.9%) |
 Unknown | 17 (3.8%) |
AJCC-M Stage | |
 M0 | 402 (89.9%) |
 M1 | 21 (4.7%) |
 Unknown | 24 (5.4%) |
Sample Type | |
 Primary tumor | 95 (21.2%) |
 Metastatic | 352 (78.8%) |